After one-month dual antiplatelet therapy (DAPT) with aspirin and ticagrelor, a net clinical benefit was observed when de-escalating to clopidogrel in acute myocardial infarction (AMI) patients treated with PCI. We have discussed the pros and cons of de-escalating from a potent antiplatelets Such as ticagrelor to clopidogrel since the TOPIC presented at EuroPCR in 2017. What<a href="https://solaci.org/en/2021/05/18/acc-2021-talos-ami-de-escalating-from-ticagrelor-to-clopidogrel-after-one-month/" title="Read more" >...</a>
LATAMBif Registry: February 2021 Report
The Latin American Registry of Percutaneous Coronary Bifurcations continues to develop at a steady pace. The aim of this prospective multicenter registry is to assess the reality of percutaneous coronary bifurcation to define its needs and establish effective strategies to perfect the daily clinical practice. Bellow you will find data from February 2021, which includes<a href="https://solaci.org/en/2021/03/09/latambif-registry-february-2021-report/" title="Read more" >...</a>
LATAMBif Registry: January 2021 Report
The Latin American Registry of Percutaneous Coronary Bifurcations continues to develop at a steady pace. The aim of this prospective multicenter registry is to assess the reality of percutaneous coronary bifurcation to define its needs and establish effective strategies to perfect the daily clinical practice. Bellow you will find data from January 2021, which includes<a href="https://solaci.org/en/2021/02/10/latambif-registry-january-2021-report/" title="Read more" >...</a>
High Risk Anatomy Challenges ISCHEMIA Outcomes
According to this recent analysis published in JAHA, patients with stable Ischemic heart disease and high-risk anatomy benefit from revascularization at long term vs. the conservative treatment. This goes against the study presented by Reynolds H et al at AHA 2020. Dr. Reynold’s was a sub-study of the ISCHEMIA trial which had observed that even<a href="https://solaci.org/en/2021/01/08/high-risk-anatomy-challenges-ischemia-outcomes/" title="Read more" >...</a>
The Most Read Articles in Interventional Cardiology
01- Ticagrelor or Prasugrel in ST Elevation MI In patients undergoing ST elevation acute myocardial infarction (STEMI) receiving primary PCI, no significative differences between prasugrel and ticagrelor were found. However, the latter was associated to a significantly higher number of repeat MI when considered separately. Read more HERE 02- Number of Hours of Sleep and<a href="https://solaci.org/en/2020/12/02/the-most-read-articles-in-interventional-cardiology/" title="Read more" >...</a>
Antiplatelet Therapy in Elderly Population: Are the New P2Y12 Inhibitors Safe?
Should elderly patients stick to clopidogrel? The first large study on prasugrel showed an unacceptable increase of bleeding in elderly patients, suggesting the use of 5 mg (although the sample size was small, which hindered the determination of dose efficacy). Later, ticagrelor showed better efficacy than clopidogrel without apparent safety concerns. However, specific evidence on elderly<a href="https://solaci.org/en/2020/11/12/antiplatelet-therapy-in-elderly-population-are-the-new-p2y12-inhibitors-safe/" title="Read more" >...</a>
Ticagrelor or Prasugrel in ST Elevation MI
In patients undergoing ST elevation acute myocardial infarction (STEMI) receiving primary PCI, no significative differences between prasugrel and ticagrelor were found. However, the latter was associated to a significantly higher number of repeat MI when considered separately. Few studies have compared the efficacy and safety of the two most potent oral P2Y12 receptor inhibitors in<a href="https://solaci.org/en/2020/11/12/ticagrelor-or-prasugrel-in-st-elevation-mi/" title="Read more" >...</a>
Is Loading NSTEMI with DAPT Convenient?
Pretreating non-ST elevation acute myocardial infarction (NSTEMI) patients with P2Y12 receptor inhibitors is not associated with improved clinical outcomes as it is to increased bleeding. NSTEMI patients are often treated with platelet antiaggregants in the daily clinical practice despite the lack of evidence for its benefits. This Swedish registry prospectively included 64857 patients undergoing NSTEMI<a href="https://solaci.org/en/2020/10/28/is-loading-nstemi-with-dapt-convenient/" title="Read more" >...</a>
ESC 2020 | Ticagrelor Might Increase Bleeding and Mortality in the Elderly
Ticagrelor compared against clopidogrel produces more bleeding and also more deaths in patients over 80 recently undergoing acute myocardial infarction. Contrary to what has been observed in the general population, these data from the SWEDEHEART registry of post MI patients over 80, show higher bleeding and mortality rates with ticagrelor compared against clopidogrel. These findings<a href="https://solaci.org/en/2020/09/09/esc-2020-ticagrelor-might-increase-bleeding-and-mortality-in-the-elderly/" title="Read more" >...</a>
ESC 2020 | Rivaroxaban Might Reduce Cardiac Cerebral and Peripheral Events
Adding rivaroxaban to the standard treatment might reduce events incidence in lower limbs, heart, and brain, in patients with peripheral vascular disease undergoing revascularization. These new data resulted from the analysis of the VOYAGER PAD subgroups and were presented at the virtual ESC 2020. The COMPASS study had reached similar conclusions using 2.5 mg rivaroxaban<a href="https://solaci.org/en/2020/09/09/esc-2020-rivaroxaban-might-reduce-cardiac-cerebral-and-peripheral-events/" title="Read more" >...</a>